Medical Treatment of Gallstone Disease

  • Piero Portincasa
  • Antonio Moschetta
  • Francesco Puglisi
  • Luigi Borracino
  • David Q. -H. Wang


Gallstones are one of the most prevalent and costly digestive diseases [1]. About 75% of the gallstones in the United States and other westernized countries are cholesterol gallstones, which are subclassified as either pure cholesterol or mixed stones that contain at least half cholesterol by weight. The remaining gallstones are pigment stones that contain mostly calcium bilirubinate and are subclassied into two groups: black pigment stones (20%) and brown pigment stones (5%).


Bile Acid Gallbladder Cancer Shock Wave Lithotripsy Gallstone Disease Cholesterol Gallstone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Portincasa P, Moschetta A, Palasciano G (2006) Cholesterol gallstone disease. Lancet 368:230–239PubMedCrossRefGoogle Scholar
  2. 2.
    Portincasa P, Moschetta A, Petruzzelli M et al (2006) Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 20:1017–1029PubMedCrossRefGoogle Scholar
  3. 3.
    Diehl AK, Sugarek NJ, Todd KH (1990) Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med 89:29–33PubMedCrossRefGoogle Scholar
  4. 4.
    Paumgartner G, Carr-Locke DL, Roda E et al (1988) Biliary stones: non-surgical therapeutic approach. Gastroenterology International 1:17–24Google Scholar
  5. 5.
    Jorgensen T (1989) Abdominal symptoms and gallstone disease: an epidemiological investigation. Hepatology 9:856–860PubMedCrossRefGoogle Scholar
  6. 6.
    Berhane T, Vetrhus M, Hausken T et al (2006) Pain attacks in non-complicated and complicated gallstone disease have a characteristic pattern and are accompanied by dyspepsis in most patients: the results of a prospective study. Scand J Gastroenterol 41:93–101PubMedCrossRefGoogle Scholar
  7. 7.
    Friedman GD, Raviola CA, Fireman B (1989) Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 42:127–136PubMedCrossRefGoogle Scholar
  8. 8.
    Gibney EJ (1990) Asymptomatic gallstones. Br J Surg 77:368–372PubMedCrossRefGoogle Scholar
  9. 9.
    Festi D, Sottili S, Colecchia A et al (1999) Clinical manifestations of gallstone disease: evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology 30:839–846PubMedCrossRefGoogle Scholar
  10. 10.
    Thistle JL, Cleary PA, Lachin JM et al (1984) The natural history of cholelithiasis: the National Cooperative Gallstone Study. Ann Intern Med 101:171–175PubMedGoogle Scholar
  11. 11.
    Venneman NG, Renooij W, Rehfeld JF et al (2005) Small gallstones, preserved gallbladder motility, and fast crystallization are associated with panreatitis. Hepatology 41:738–746PubMedCrossRefGoogle Scholar
  12. 12.
    Venneman NG, Buskens E, Besselink MG et al (2005) Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy? Am J Gastroenterol 100:2540–2550PubMedCrossRefGoogle Scholar
  13. 13.
    Paumgartner G, Carr-Locke DL, Dubois F et al (1993) Strategies in the treatment of gallstone disease. Working team report. Gastroenterology International 6:65–75Google Scholar
  14. 14.
    Brugge WR (2000) The silent gallstone. In: gallbladder and biliary tract diseases. Afdhal NH (ed). New York, Basel, Marcel Dekker, Inc., pp 447–453Google Scholar
  15. 15.
    Tait N, Little JM (1995) The treatment of gall stones. BMJ 311:99–105PubMedGoogle Scholar
  16. 16.
    Hofmann AF, Amelsberg A, Vansonnenberg E (1993) Pathogenesis and treatment of gallstones. N Engl J Med 328:1854–1855PubMedCrossRefGoogle Scholar
  17. 17.
    Johnston DE, Kaplan MM (1993) Pathogenesis and treatment of gallstones. N Engl J Med 328:412–421PubMedCrossRefGoogle Scholar
  18. 18.
    Pokorny WJ, Saleem M, O’Gorman RB et al (1984) Cholelithiasis and cholecystitis in childhood. Am J Surg 148:742–744PubMedCrossRefGoogle Scholar
  19. 19.
    Amaral JF, Thompson WR (1985) Gallbladder disease in the morbidly obese. Am J Surg 149:551–557PubMedCrossRefGoogle Scholar
  20. 20.
    Sleisenger MH, Fordtran JS (2006) Gastrointestinal disease; pathophysiology, diagnosis, management, 8th edn. Philadelphia, W.B. SaundersGoogle Scholar
  21. 21.
    Lowenfels AB, Walker AM, Althaus DP et al (1989) Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol 18:50–54PubMedCrossRefGoogle Scholar
  22. 22.
    Randi G, Franceschi S, La VC (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591–1602PubMedCrossRefGoogle Scholar
  23. 23.
    Ashur H, Siegal B, Oland Y et al (1978) Calcified ballbladder (porcelain gallbladder). Arch Surg 113:594–596PubMedGoogle Scholar
  24. 24.
    Lowenfels AB, Lindstrom CG, Conway MJ et al (1985) Gallstones and risk of gallbladder cancer. J Natl Cancer Inst 75:77–80PubMedGoogle Scholar
  25. 25.
    Bonatsos G, Birbas K, Toutouzas K et al (2001) Laparoscopic cholecystectomy in adults with sickle cell disease. Surg Endosc 15:816–819PubMedCrossRefGoogle Scholar
  26. 26.
    Graham SM, Flowers JL, Schweitzer E et al (1995) Opportunistic upper gastrointestinal infection in transplant recipients. Surg Endosc 9:146–150PubMedCrossRefGoogle Scholar
  27. 27.
    Graham SM, Flowers JL, Schweitzer E et al (1995) The utility of prophylactic laparoscopic cholecystectomy in transplant candidates. Am J Surg 169:44–48PubMedCrossRefGoogle Scholar
  28. 28.
    Kao LS, Kuhr CS, Flum DR (2003) Should cholecystectomy be performed for asymptomatic cholelithiasis in transplant patients? J Am Coll Surg 197:302–312PubMedCrossRefGoogle Scholar
  29. 29.
    Shiffman ML, Sugerman HJ, Kellum JH et al (1993) Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility. Int J Obes 17:153–158Google Scholar
  30. 30.
    Shiffman ML, Sugerman HJ, Kellum JM et al (1991) Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 86:1000–1005.PubMedGoogle Scholar
  31. 31.
    Liem RK, Niloff PH (2004) Prophylactic cholecystectomy with open gastric bypass operation. Obes Surg 14:763–765PubMedCrossRefGoogle Scholar
  32. 32.
    Lee SP, Nicholls JF, Park HZ (1992) Biliary sludge as a cause of acute pancreatitis. N Engl J Med 326:589–593PubMedGoogle Scholar
  33. 33.
    Ros E, Navarro S, Bru C et al (1991) Occult microlithiasis in ‘idiopathic’ acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy [see comments]. Gastroenterology 101:1701–1709PubMedGoogle Scholar
  34. 34.
    National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy. Am J Surg (1993) 165:390–398CrossRefGoogle Scholar
  35. 35.
    Schoenfield LJ, Carulli N, Dowling RH et al (1989) Asymptomatic gallstones: definition and treatment. Gastroenterology International 2:25–29Google Scholar
  36. 36.
    Sauerbruch T, Paumgartner G (1991) Gallbladder stones: management. Lancet 338;1121–1124PubMedCrossRefGoogle Scholar
  37. 37.
    Kumar A, Deed JS, Bhasin B et al (2004) Comparison of the effect of diclofenac with hyoscine-N-butylbromide in the symptomatic treatment of acute biliary colic. ANZ J Surg 74:573–576PubMedCrossRefGoogle Scholar
  38. 38.
    Al-Waili N, Saloom KY (1998) The analgestic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide. Eur J Med Res 3:475–479PubMedGoogle Scholar
  39. 39.
    Akriviadis EA, Hatzigavriel M, Kapnias D et al (1997) Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Gastroenterology 113:225–231PubMedCrossRefGoogle Scholar
  40. 40.
    Goldman G, Kahn PJ, Alon R et al (1989) Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 34:809–811PubMedCrossRefGoogle Scholar
  41. 41.
    Gracie WA, Ransohoff DF (1982) The natural history of silent gallstones: the “innocent— gallstone” is not a myth. N Engl J Med 307:798–800PubMedGoogle Scholar
  42. 42.
    Friedman GD (1993) Natural history of asymptomatic and symptomatic gallstones. Am J Surg 165:399–404PubMedCrossRefGoogle Scholar
  43. 43.
    Tint GS, Salen G, Colalillo A et al. (1982) Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 97:351–356PubMedGoogle Scholar
  44. 44.
    Meredith TJ, Williams GV, Maton PN et al (1982) Retrospective comparison of ‘Cheno’ and ‘Urso’ in the medical treatment of gallstones. Gut 23:382–389PubMedCrossRefGoogle Scholar
  45. 45.
    Tomida S, Abei M, Yamaguchi T et al (1999) Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 30:6–13PubMedCrossRefGoogle Scholar
  46. 46.
    Venneman NG, Besselink MG, Keulemans YC et al (2006) Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 43:1276–1283PubMedCrossRefGoogle Scholar
  47. 47.
    Sauerbruch T, Delius M, Paumgartner G et al (1986) Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med 314:818–822PubMedGoogle Scholar
  48. 48.
    Allen MJ, Borody TJ, Bugliosi TF et al (1985) Rapid dissolution of gallstones by methyl tert-butyl ether. Preliminary observations. N Engl J Med 312:217–220PubMedGoogle Scholar
  49. 49.
    Hellstern A, Leuschner U, Benjaminov A et al (1998) Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. Dig Dis Sci 43:911–920PubMedCrossRefGoogle Scholar
  50. 50.
    Paumgartner G, Sauter GH (2005) Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment. Eur J Gastroenterol Hepatol 17:525–527PubMedCrossRefGoogle Scholar
  51. 51.
    Nunes DP (2007) Nonsurgical treatment of gallstone disease. UpToDate 1–5Google Scholar
  52. 52.
    Paumgartner G, Pauletzki J, Jackmann M (1994) Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl 204:27–31PubMedCrossRefGoogle Scholar
  53. 53.
    Leopold GR, Amberg J, Gosink BB et al (1976) Gray scale ultrasonic cholecystography: a comparison with conventional radiographic techniques. Radiology 121:445–448PubMedGoogle Scholar
  54. 54.
    Portincasa P, Di Ciaula A, Palmieri VO et al (1994) Sonographic evaluation of gallstone burden in humans. Ital J Gastroenterol Hepatol 26:141–144Google Scholar
  55. 55.
    Everson GT, Braverman DZ, Johnson ML et al (1980) A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 79:40–46PubMedGoogle Scholar
  56. 56.
    Portincasa P, Moschetta A, Colecchia A et al (2003) Measurement of gallbladder motor function by ultrasonography: towards for standardization. Dig Liver Dis (già Ital J Gastroenterol Hepatol) 35(Suppl 3):S56–S61Google Scholar
  57. 57.
    Pauletzki JG, Althaus R, Holl J et al (1996) Gallbladder emptying and gallstone formation: a prospective study on gallstone recurence. Gastroenterology 111:765–771PubMedCrossRefGoogle Scholar
  58. 58.
    Portincasa P, van Erpecum KJ, van de Meeberg PC et al (1996) Apolipoprotein (Apo) E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 24:580–587PubMedCrossRefGoogle Scholar
  59. 59.
    Venneman NG, van Berge-Henegouwen GP, Porticasa P et al (2001) Absence of apolipoprotein E4 genotype, good gallbladder motility and presence of solitary stones delay rather than prevent gallstone recurrence after extracorporeal shock wave lithotripsy. J Hepatol 135:10–16CrossRefGoogle Scholar
  60. 60.
    Festi D, Frabboni R, Bazzoli F et al (1990) Gallbladder motility in cholesterol gallstone disease. Effect of ursodeoxycholic acid administration and gallstone dissolution. Gastroenterology 99:1779–1785PubMedGoogle Scholar
  61. 61.
    Portincasa P, Di Ciaula A, Baldassarre G et al (1994) Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J Hepatol 21:430–440PubMedCrossRefGoogle Scholar
  62. 62.
    Pereira SP, Veysey MJ, Kennedy C et al (1997) Gallstone dissolution with oral bile acid therapy —Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci 42:1775–1782PubMedCrossRefGoogle Scholar
  63. 63.
    Pereira SP, Hussaini SH, Kennedy C et al (1995) Gallbladder stone recurrence after medical treatment. Do gallstones recur true to type? Dig Dis Sci 40:2568–2575PubMedCrossRefGoogle Scholar
  64. 64.
    Sherlock S, Dooley J (2002) Diseases of the liver and biliary system. Oxford, Blackwell ScienceGoogle Scholar
  65. 65.
    Sackmann M, Eder H, Spengler U et al (1993) Gallbladder emptying is an important factor in fragment disappearance after shock wave lithotripsy. J Hepatol 17:62–66PubMedCrossRefGoogle Scholar
  66. 66.
    Schiff M (1873) Il coleinato di soda nella cura dei calcoli biliari. LĽImpariziale 13:97–98Google Scholar
  67. 67.
    Dabney WC (1876) The use of choleate of soda to prevent the formation of gallstones. Am J Med Sci 71:410CrossRefGoogle Scholar
  68. 68.
    Rewbridge AG (1937) The disappearance of gallstone shadows following the prolonged administration of bile acids. Surgery 1:395–400Google Scholar
  69. 69.
    Danzinger RG, Hofmann AF, Schoenfield LJ (1972) Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 286:1–8PubMedGoogle Scholar
  70. 70.
    Makino I, Shinozaki K, Yoshino K et al (1975) [Dissolution of cholesterol gallstones by longterm administration of ursodeoxycholic acid]. Nippon Shokakibyo Gakkai Zasshi 72:690–702PubMedGoogle Scholar
  71. 71.
    Mouret P (1990) Celioscopic surgery. Evolution or revolution? Chirurgie 116:829–832PubMedGoogle Scholar
  72. 72.
    van de Heijning BJM, van de Meeberg P, Portincasa P et al (1999) Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci 44:190–196PubMedCrossRefGoogle Scholar
  73. 73.
    Guarino MP, Cong P, Cicala M et al (2007) Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 56:815–820PubMedCrossRefGoogle Scholar
  74. 74.
    van Erpecum KJ, Portincasa P, Stolk MFJ et al (1994) Effects of bile salt and phospholipid hydrophobicity on lithogenicity of human gallbladder bile. Eur J Clin Invest 24:744–750PubMedCrossRefGoogle Scholar
  75. 75.
    van Erpecum KJ, Portincasa P, Gadellaa M et al (1996) Effects of bile salt hydrophobicity on nucleation behaviour of cholesterol crystals in model bile. Eur J Clin Invest 26:602–608PubMedCrossRefGoogle Scholar
  76. 76.
    Portincasa P, van Erpecum KJ, Jansen A et al (1996) Behavior of various cholesterol crystals in bile from gallstone patients. Hepatology 23:738–748PubMedCrossRefGoogle Scholar
  77. 77.
    Moschetta A, van Berge-Henegouwen GP, Portincasa P et al (2001) Cholesterol crystalization in model biles. Effects of bile salt and phospholipid species composition. J Lipid Res 42:1273–1281PubMedGoogle Scholar
  78. 78.
    Venneman NG, Huisman SJ, Moschetta A et al (2002) Effects of hydrophobic and hydrophilic bile salt mixtures on cholesterol crystallization in model biles. Biochim Biophys Acta 1583:221–228PubMedGoogle Scholar
  79. 79.
    Venneman NG, van Kammen M, Renooij W et al (2005) Effects of hydrophobic and hydrophilic bile salts on gallstone growth and dissolution in model biles. Biochim Biophys Acta 3:209–219Google Scholar
  80. 80.
    Sugerman HJ, Brewer WH, Shiffman ML et al (1995) A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg 169:91–96PubMedCrossRefGoogle Scholar
  81. 81.
    Paumgartner G (1996) Therapeutic options and choice of appropriate treatment. In: Bile acids — Cholestatis — Gallstones. Advances in basic and clinical bile acid research. Dordrecht, Kluwer Academic Publishers, pp 205–210Google Scholar
  82. 82.
    Sackmann M, Ippisch E, Sauerbruch T et al (1990) Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology 98:392–396PubMedGoogle Scholar
  83. 83.
    Villanova N, Bazzoli F, Taroni F et al (1989) Gallstone recurrence after successful oral bile acid treatment: a 12 year follow-up study and evaluation of long term postdissolution treatment. Gastroenterology 97:726–731PubMedGoogle Scholar
  84. 84.
    Petroni ML, Jazrawi RP, Pazzi P et al (2000) Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 12:695–700PubMedCrossRefGoogle Scholar
  85. 85.
    Wang DQH, Carey MC (1996) Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing system. J Lipid Res 37:606–630PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Piero Portincasa
    • 1
  • Antonio Moschetta
    • 1
    • 2
  • Francesco Puglisi
    • 3
  • Luigi Borracino
    • 1
  • David Q. -H. Wang
    • 4
  1. 1.Department of Internal Medicine and Public Medicine Clinica Medica A. MurriUniversity of Bari Medical SchoolBariItaly
  2. 2.Department of Translational PharmacologyConsorzio Mario Negri SudSanta Maria Imbaro (Chieti)Italy
  3. 3.Section of Surgery Department of Emergency and Transplant Organs (DETO)University of Bari Medical SchoolBariItaly
  4. 4.Gastroenterology Division Beth Israel Deaconess Medical Center Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations